Xceleron teams with Chinese CRO for early development

Drug-development specialist Xceleron is partnered with Crystal Pharmatech, and the two plan to pool their early-stage resources and offer clients quick bioavailability data for their compounds.

Neither company disclosed the financial details, but the China-based Crystal brings its solid-state research expertise to complement Xceleron's tests for pharmacokinetics in early-stage development.

Too often, drug efficacy suffers in modern small-molecule development because researchers can't properly account for unpredictable biological models, Xceleron says, but the CROs' combined efforts can help sponsors make quick decisions about a candidate's long-term viability.

"Having robust bioavailability and pharmacokinetic data at the outset provides a strong foundation for determining the best solid form and formulation," Alex Chen, CEO of Crystal Pharmatech, said in a statement. "Each company brings significant expertise to the discussion of novel clinical outcomes."

- read the announcement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.